Founded in 2013 in Northern Ireland, Axis Bio is a preclinical contract research organization (CRO) specializing in early drug discovery. The company is recognized for its scientific expertise and collaborative approach, delivering tailored preclinical models that support informed decision-making in complex research programmes. In 2025, Axis Bio joined the QIMA group, strengthening QIMA Life Sciences’ scientific capabilities and expanding its international footprint across preclinical research services in oncology, immunology and metabolic disorders.
Axis Bio supports clients across the pharmaceutical and biotechnology ecosystem with customized preclinical research services.
Services include:
In vitro and ex vivo efficacy and mechanistic studies
Preclinical pharmacology, PK/PD and biodistribution studies
Disease-relevant models in oncology, inflammation and respiratory research
Integrated bioanalysis, biomarker assessment and data interpretation
Industries served include:
Pharmaceutical companies
Biotechnology organizations
Academic and translational research institutions
Axis Bio is trusted for its ability to design fully bespoke scientific solutions aligned to each project’s research objectives. Its teams combine deep disease-area expertise with a partnership-driven mindset, acting as an extension of client research teams rather than a transactional service provider. Clients value the quality, reliability and interpretability of the data generated, as well as the agility and efficiency with which Axis Bio supports innovative and early-stage programmes.
Axis Bio operates in accordance with rigorous scientific, ethical and quality standards applicable to preclinical research. Its facilities, methodologies and data generation processes are designed to support robust, reliable and decision-ready preclinical outcomes in line with industry and regulatory expectations.
As part of the QIMA group, Axis Bio complements QIMA Life Sciences’ broader testing and research capabilities, extending support into early-stage drug discovery. This integration enables clients to access preclinical expertise alongside downstream testing, evaluation and compliance services within a single, globally recognized organization.
To learn more about Axis Bio’s preclinical research capabilities and how they integrate with QIMA Life Sciences, contact our team.